# Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study in China

> **NCT02898922** · PHASE4 · COMPLETED · sponsor: **Shandong Province Centers for Disease Control and Prevention** · enrollment: 300 (actual)

## Conditions studied

- Hepatitis B Vaccines

## Interventions

- **BIOLOGICAL:** hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae

## Key facts

- **NCT ID:** NCT02898922
- **Lead sponsor:** Shandong Province Centers for Disease Control and Prevention
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-01
- **Final completion:** —
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2016-09-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02898922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02898922, "Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study in China". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02898922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*